Prediction	O
of	O
pharmacokinetic	O
and	O
toxicological	O
parameters	O
of	O
a	O
4	B:C0299275
-	I:C0299275
phenylcoumarin	I:C0299275
isolated	O
from	O
geopropolis	B:C1254351
:	O

In	O
silico	O
and	O
in	O
vitro	O
methodologies	O
have	O
been	O
used	O
as	O
important	O
tools	O
in	O
the	O
drug	B:C0920472
discovery	I:C0920472
process	O
,	O
including	O
from	O
natural	B:C0243095
sources	I:C0243095
.	O

The	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
predict	O
pharmacokinetic	O
and	O
toxicity	O
(	O
ADME	B:C1510686
/	O
Tox	O
)	O
properties	O
of	O
a	O
coumarin	B:C0010206
isolated	O
from	O
geopropolis	B:C1254351
using	O
in	O
silico	O
and	O
in	O
vitro	O
approaches	O
.	O

Cinnamoyloxy	B:C1254351
-	I:C1254351
mammeisin	I:C1254351
(	O
Cinnamoyloxy	B:C1254351
-	I:C1254351
mammeisin	I:C1254351
)	O
isolated	O
from	O
Brazilian	B:C0006137
M.	B:C1499394
scutellaris	I:C1499394
geopropolis	B:C1254351
was	O
evaluated	O
for	O
its	O
pharmacokinetic	O
parameters	O
by	O
in	O
silico	O
models	O
(	O
ACD	B:C0282574
/	I:C0282574
Percepta™	I:C0282574
and	O
MetaDrug™	B:C0282574
software	I:C0282574
)	O
.	O

Genotoxicity	O
was	O
assessed	O
by	O
in	O
vitro	O
DNA	B:C0012860
damage	I:C0012860
signaling	O
PCR	B:C3899376
array	I:C3899376
.	O

Cinnamoyloxy	B:C1254351
-	I:C1254351
mammeisin	I:C1254351
did	O
not	O
pass	O
all	O
parameters	B:C0282574
of	O
Lipinski's	B:C0282574
rule	I:C0282574
of	I:C0282574
five	I:C0282574
,	O
with	O
a	O
predicted	O
low	O
oral	B:C0442027
bioavailability	O
and	O
high	O
plasma	B:C0032119
protein	I:C0032119
binding	I:C0032119
,	O
but	O
with	O
good	O
predicted	O
blood	O
brain	O
barrier	O
penetration	O
.	O

Cinnamoyloxy	B:C1254351
-	I:C1254351
mammeisin	I:C1254351
was	O
predicted	O
to	O
show	O
low	O
affinity	O
to	O
cytochrome	B:C0010762
P450	I:C0010762
family	I:C0010762
members	O
.	O

Furthermore	O
,	O
the	O
predicted	O
Ames	O
test	O
indicated	O
potential	O
mutagenicity	O
of	O
Cinnamoyloxy	B:C1254351
-	I:C1254351
mammeisin	I:C1254351
.	O

Also	O
,	O
the	O
probability	O
of	O
toxicity	O
for	O
organs	B:C0178784
and	O
tissues	B:C0040300
was	O
classified	O
as	O
moderate	O
and	O
high	O
for	O
liver	B:C0023884
and	O
kidney	B:C0022646
,	O
and	O
moderate	O
and	O
low	O
for	O
skin	B:C0152030
and	O
eye	B:C0235266
irritation	I:C0235266
,	O
respectively	O
.	O

The	O
PCR	B:C3899376
array	I:C3899376
analysis	O
showed	O
that	O
Cinnamoyloxy	B:C1254351
-	I:C1254351
mammeisin	I:C1254351
significantly	O
upregulated	B:C0041904
about	O
7	O
%	O
of	O
all	O
DNA	B:C0012860
damage	I:C0012860
-	I:C0012860
related	I:C0012860
genes	B:C0017337
.	O

By	O
exploring	O
the	O
biological	B:C3714634
function	I:C3714634
of	O
these	O
genes	B:C0017337
,	O
it	O
was	O
found	O
that	O
the	O
predicted	O
Cinnamoyloxy	B:C1254351
-	I:C1254351
mammeisin	I:C1254351
genotoxicity	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
apoptosis	B:C0162638
.	O

The	O
predicted	O
ADME	B:C1510686
/	O
Tox	O
profile	O
suggests	O
that	O
external	O
use	O
of	O
Cinnamoyloxy	B:C1254351
-	I:C1254351
mammeisin	I:C1254351
may	O
be	O
preferable	O
to	O
systemic	O
exposure	O
,	O
while	O
its	O
genotoxicity	O
was	O
characterized	O
by	O
the	O
upregulation	B:C0041904
of	O
apoptosis	B:C0162638
-	I:C0162638
related	I:C0162638
genes	B:C0017337
after	O
treatment	B:C0087111
.	O

The	O
combined	O
use	O
of	O
in	O
silico	O
and	O
in	O
vitro	O
approaches	O
to	O
evaluate	O
these	O
parameters	B:C0282574
generated	O
useful	O
hypotheses	O
to	O
guide	O
further	O
preclinical	B:C1709631
studies	I:C1709631
.	O

